EP3500182B1 - Pointes de pulvérisation pour distribution simultanée multidirectionnelle de fluides dissemblables - Google Patents

Pointes de pulvérisation pour distribution simultanée multidirectionnelle de fluides dissemblables Download PDF

Info

Publication number
EP3500182B1
EP3500182B1 EP17772786.4A EP17772786A EP3500182B1 EP 3500182 B1 EP3500182 B1 EP 3500182B1 EP 17772786 A EP17772786 A EP 17772786A EP 3500182 B1 EP3500182 B1 EP 3500182B1
Authority
EP
European Patent Office
Prior art keywords
component
spray tip
spray
exit orifices
distribution compartment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP17772786.4A
Other languages
German (de)
English (en)
Other versions
EP3500182A1 (fr
Inventor
Sridevi Dhanaraj
Ashley Deanglis
John F. Goodman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ethicon Inc
Original Assignee
Ethicon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethicon Inc filed Critical Ethicon Inc
Priority to EP20197424.3A priority Critical patent/EP3788964A1/fr
Publication of EP3500182A1 publication Critical patent/EP3500182A1/fr
Application granted granted Critical
Publication of EP3500182B1 publication Critical patent/EP3500182B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A61M11/007—Syringe-type or piston-type sprayers or atomisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00491—Surgical glue applicators
    • A61B2017/00495—Surgical glue applicators for two-component glue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids

Definitions

  • the present disclosure relates to spray tip assemblies for use with devices that apply two or more biocompatible, hemostatic, adhesive and/or sealing components without independently of one another while simultaneously spraying the components multidirectionally.
  • Drip devices for dispensing two or more biocomponents are known.
  • such devices are typically used for applying bioadhesives, polymers and other synthetic material used in wound closure.
  • mixing of the components does not occur until the solution is ready to be applied. Mixing of the components too soon before application may result in the premature polymerization reaction or hardening of the mixture, thereby making application of the solution impossible.
  • the two or more components are maintained separately until just prior to application.
  • the drip devices may include one or more pre-mixing means for mixing the two or more solutions prior to application.
  • the pre-mixing means may be passive, i.e., spiral configuration in the tubing, or instead may be active, i.e., mixing blade or impeller. Once mixed, the solution may be applied through a needle-like output or may instead be ejected through a spray assembly.
  • WO 2014/113414 A1 relates to a device for applying a two part adhesive or sealant to an anastomosis site prior to stapling with a circular anastomosis surgical stapling instrument, the device having a hollow housing having a top surface and an opposing bottom surface with at least two separate channels within said housing, a plurality of nozzles disposed circumferentially on the top surface and on the bottom surface with the nozzles in fluid communication with the channels, a manifold connector attached to the housing, the connector being in fluid communication with the channels and adapted to be connected to a dual lumen cannula supplying sealant components, and a coupler adapted to mount the device to the circular anastomosis surgical stapling instrument.
  • US 2003/191496 A1 relates to Systems and methods for introducing a closure material to seal a vessel puncture site.
  • the system and methods provide a catheter adapted for passage through a tissue puncture and sized to occupy substantially all the tissue puncture.
  • WO 2006/102472 A1 relates to a multi-compartment liquid dispensing device includes an outer container defining a first chamber for accommodating a first liquid and an inner container disposed within the outer container defining a second chamber for accommodating a second liquid.
  • the dispensing device additionally includes a dispensing unit connected to the inner and outer containers, and has a plurality of passages configured to allow for the exiting of the first and second liquids separately and simultaneously from the dispensing device, regardless of its angular orientation.
  • WO 02/055138 A1 relates to a device for dispensing at least two mutually reactive components, such as fibrino-gen and thrombin, comprising a supplier having a primary channel for supplying a respective one of said at least two reactive components to a dispenser having secondary channels for separately discharging said components at a distal end orifice thereof opening into a target area for external intimate mixing of the respective reactive components outside a distal tip end of said dispenser.
  • a supplier having a primary channel for supplying a respective one of said at least two reactive components to a dispenser having secondary channels for separately discharging said components at a distal end orifice thereof opening into a target area for external intimate mixing of the respective reactive components outside a distal tip end of said dispenser.
  • US 2008/317539 A1 relates to an applicator for two or more components, in particular for an adjustable metering dispenser in which the components are only mixed at an applicator surface with outlet apertures, the outlet apertures for one of the components and for the other component extend separately up to the applicator surface and are brought together to a point at the applicator surface.
  • Persistent air leaks occurring after lung resection procedures are associated with patient discomfort, and increased length and cost of hospitalization.
  • Sealing air leaks has been identified as a significant unmet need, however, there is currently no standard for treatment or prevention. More than 800,000 lung resection procedures are performed globally each year, and the number of procedures is expected to grow in future years as new lung cancer screening guidelines are implemented. Leaks are associated with increased length and cost of hospitalization, patient discomfort and prolonged chest tube management. Rates of persistent air leaks are 15-18% for non-emphysematous patients and up to 50% for patients with emphysema and COPD. The properties of existing sealants also make it difficult to ensure full and continued coverage of the lung, particularly when a minimally invasive technique has been used.
  • Full coverage of the lung is important, because a) leaks can develop at the staple line, adjacent to the staple line, and in the lobes of the lung due to manipulation during the procedure b) the exact location of air leaks in not known.
  • Current sealants must be applied to a deflated lung. Current sealants do not have the physical properties that allow them to maintain coverage of the entire surface of the lung during and after insufflation. Current sealants are applied to the lung in a deflated state and following sealant set, the lung is fully inflated. This results in a several fold change in lung volume, while the sealant in unable to expand to the same degree resulting in sealant crack and loss of seal.
  • U.S. Patent No. 5,605,541 titled “Fibrin sealant applicator” discloses a device for applying a fibrin sealant comprising two components which will form said sealant when combined, which device comprises reservoirs for each of said components and a source of gas, wherein each of said reservoirs and said gas in separate fluid communication via a discrete channel to a spray head, said spray head having a first aperture located centrally in an exit end of said spray head through which said gas is discharged, said spray head having a first annular aperture in the exit end of said spray head within first annular aperture is concentric with said first aperture and through which one of said fibrin-sealant-forming components is discharged, and a second annular aperture in the exit end of said spray head being concentric with said first aperture and concentric with, and having a radius larger than said first annular aperture through which the second of said fibrin-sealant-forming components is discharged wherein all of said apertures are in a common plane.
  • U.S. Patent No. 5,759,169 titled “Fibrin sealant glue-gun” discloses an applicator for creating a homogeneous film coating of a biological adhesive, the adhesive comprising a first component and a second component, the applicator comprising: (a) a housing having a first dispensing conduit for dispensing said first component and a second dispensing conduit for dispensing said second component; (b) a pressure supply conduit in communication with said dispensing conduits; (c) a first reservoir containing said first component, said first reservoir being in communication with said first dispensing conduit; (d) a second reservoir containing said second component, said second reservoir being in communication with said second dispensing conduit; (e) a first pressure regulator in communication with said first reservoir for controlling pressure supplied through said pressure supply conduit to said first reservoir; and (f) a second pressure regulator in communication with said second reservoir for controlling pressure supplied through said pressure supply conduit to said second reservoir.
  • U.S. Patent No. 6,132,396 titled “Apparatus for applying tissue sealant” discloses a manifold for combining first and second components of a material, comprising a body having first and second inlet ports, a tubular dispenser coupled to the body and provided with an outlet and an internal passageway in fluid communication with said outlet, said body having first fluid transport means adapted for transporting said first component from said first inlet port to said internal passageway and second fluid transport means adapted for transporting said second component from said second inlet port to said internal passageway, said first fluid transport means including a hypodermic needle in fluid connection with said first inlet port and having an outlet disposed within said internal passageway, said second fluid transport means including a channel in the body and in fluid connection with said second inlet port and provided with an outlet disposed within said internal passageway the hypodermic needle is located in or able to penetrate the channel whereby said first and second components are directed by said first and second transport means into said tubular dispenser for mixing prior to discharge from the outlet of said tubular dispenser.
  • U.S. Patent No. 6,461,325 titled "Fibrin delivery device and method for forming fibrin on a surface” discloses a medical device for delivering volumetric quantities of a first and second biochemically active fluid comprising: a first container adapted to contain the first biochemically reactive fluid and having a first fluid channel; a second container adapted to contain the second biochemically reactive fluid and having a second fluid channel; an atomizer in fluid communication with the first and second channels for separately atomizing the first and second biochemically reactive fluids into an aerosol with at least one energy source of a liquid energy, a mechanical energy, a vibration energy, and an electric energy; a fluid pressurizer for delivering a third fluid under pressure to the first container and the second container to deliver the first fluid and the second fluid under pressure to the atomizer; and a third channel for delivering a catalyst.
  • U.S. Patent No. 6,863,660 titled “Fibrin applicator pistol” discloses an applicator for delivering a homogeneous coating of fibrin glue formed from a first component and a second component to a target surface comprising: a first hermetically sealed reservoir containing said first component and having a first inlet conduit in fluid communication with said first component; a second hermetically sealed reservoir containing said second component and having a second inlet conduit in fluid communication with said second component; means for applying positive fluid pressure to said first and second hermetically sealed reservoirs relative to an ambient environment; a first outlet conduit in fluid communication with said first component and terminated by a first atomizer extending into said ambient environment in a first direction and having a first inner diameter; and a second outlet conduit in fluid communication with said second component and terminated by a second atomizer extending into said ambient environment in a second direction intersecting with said first direction and having a second inner diameter; wherein application of fluid pressure to said first and second hermetically sealed reservoirs generates a first her
  • U.S. Patent No. 8,731,841 titled “Compositions and methods for therapeutic delivery with frozen particles” discloses a system comprising: at least one computing device; at least one computer program, configured with a computer-readable medium, for use with at least one computer system and wherein the computer program includes a plurality of instructions that when executed on the computing device cause the computing device to direct a predetermined patterned delivery of a plurality of frozen particle therapeutic compositions to at least one biological tissue of at least one subject by a remote controlled device, the plurality of frozen particle therapeutic compositions including at least two sub-sets of frozen particles that include different therapeutic agents and at least one tracer agent; and compare information related to the delivery with information regarding at least one clinical outcome following receipt by the at least one subject; and at least one imaging device configured to measure the at least one tracer agent and provide real-time feedback control of the plurality of frozen particle therapeutic compositions administered to the at least one subject.
  • U.S. Patent Application Publication No. 2011/0264122A1 titled “DEVICE FOR APPLYING GLUE ON TISSUES TO BE CONNECTED” discloses a device for applying a connecting glue to the facing extremities of two portions of tissue to be connected through enteric anastomosis performable with a mechanical suturer, the device comprising a diffusing element suppliable with the glue and interposable between the two portions of tissue to be connected, the diffusing element provided with at least two openings for bilateral delivery of the glue towards the two portions of tissue to be connected, wherein said diffusing element is connected in fluid communication to a first sheath, wherein said device is connected to a dispenser of aeriforms under pressure for delivering said aeriform inside the first sheath for nebulising the connecting glue delivered by the diffusing element to the portions of tissue to be connected, and wherein said diffusing element has a deployable structure for cooperating with said mechanical suturer.
  • U.S. Patent No. 8,281,975 titled "Surgical apparatus and structure for applying sprayable wound treatment material” discloses a surgical stapling apparatus, comprising: a body portion including a proximal end and a distal end, the body portion supporting an actuating handle member at the proximal end thereof and a staple pusher member at the distal end thereof; an anvil assembly removably mounted at the distal end of the body portion, the anvil assembly is movable toward and away from the body portion; an approximation assembly extending between and operatively connected to the body portion and the anvil assembly, wherein the approximation assembly moves the anvil assembly toward and away from the body portion, the approximation assembly including a shaft configured for releasable connection with the anvil assembly; and a wound treatment material dispersion assembly operatively associated with the approximation assembly, the dispersion assembly including: at least one fluid source, at least one conduit in fluid communication with the at least one fluid source and extending into the shaft of the
  • U.S. Patent No. 9,119,606 titled "Sealant delivery device for anastomotic stapler” discloses a circular anastomosis surgical stapling instrument, comprising: a shaft, an anvil, a stapling head, and a device for applying adhesive components or sealant components to anastomosis site; the device comprising: a hollow housing with a plurality of exit openings and a coupler adapted to mount the device to the shaft of the circular anastomosis surgical stapling instrument; wherein the hollow housing having a top surface and an opposing bottom surface with at least two separate channels within said housing; the plurality of exit openings comprise a plurality of nozzles disposed circumferentially on the to surface and on the bottom surface with the plurality of nozzles in fluid communication with the channels; a manifold connector attached to the hollow housing, the manifold connector is in fluid communication with the channels and adapted to be connected to a dual lumen cannula for supplying the adhesive
  • U.S. Patent Application Publication No. 2011/0147432A1 titled “STRUCTURE FOR APPLYING SPRAYABLE WOUND TREATMENT MATERIAL” discloses a wound treatment material dispersion system for use in combination with an anastomotic surgical stapling apparatus, wherein the surgical stapling apparatus includes an anvil assembly supported opposite a staple pusher member, wherein the wound treatment material dispersion system comprises: a disc defining an outer edge and an inner edge, the disc including a plurality of apertures formed therethrough; at least one of an annular inner wall integrally connected to the inner edge of the disc and an annular outer wall integrally connected to the outer edge; and wound treatment material disposed on a surface of the disc.
  • U.S. Patent No. 9,254,346 titled "Vascular closure device having a flowable sealing material” discloses a vascular closure device comprising: a hollow, perforated tube; sealing material configured to flow out of the perforated tube and into a tissue tract to close a hole in a blood vessel; a vessel locating member insertable through the perforated tube and the hole, the vessel locating member being axially movable relative to the perforated tube and the hole, the vessel locating member being expandable within the vessel to temporarily seal the hole internally, the vessel locating member comprising a tube having a plurality of slits extending along a length thereof to define a plurality of deformable arms; wherein the vascular closure device is configured to be inserted into the tissue tract; wherein the vascular closure device comprises a plurality of holes so that the sealing material flows out of the vascular closure device into the tissue tract in a direction that is not parallel to the tissue tract, wherein the plurality of holes increase in size moving distally along
  • U.S. Patent Application Publication No. 2015/0005698 titled "Applicator” discloses an applicator, comprising: a nozzle including an elongated nozzle main body, to which gas and a plurality of kinds of liquids are supplied, and a nozzle head at a distal end of the nozzle main body and configured to jet a mixed solution of the gas and the plurality of kinds of liquids supplied to the nozzle main body, the nozzle main body possessing an outer peripheral surface; a sheath in which the nozzle main body is positioned for relative movement along a longitudinal direction of the nozzle main body, the sheath possessing an inner peripheral surface; the applicator being insertable into a living body to apply the mixed solution to a region in the living body; a gap between the outer peripheral surface of the nozzle main body and the inner peripheral surface of the sheath that is an exhaust path for exhausting gas in the living body to outside of the living body when the pressure in the living body rises; and the sheath including a plurality of side holes
  • U.S. Patent No. 8,888,749 titled "Spray for fluent materials” discloses a medical apparatus for applying a biocompatible coating in situ, the apparatus comprising: an elongated barrel having a distal end defining a gas flow outlet; and first and second conduits each having a distal end extending through the gas flow outlet and beyond the distal end of the elongated barrel, the first conduit defining a first exit opening and the second conduit defining a second exit opening, the first and second conduits are configured to deliver a first composition through the first conduit and a second composition through the second conduit, the first and second exit openings are positioned externally of the elongated barrel distally of the gas flow outlet to mix the first composition and the second composition externally of the elongated barrel and the first and second conduits, wherein the distal end of the first conduit has a first beveled tip defining the first exit opening, the first beveled tip defining a first plane having a first axis which is angled with respect to a
  • U.S. Patent No. 7,776,063 titled "In situ materials formation” discloses a method of disposing a crosslinked biocompatible material in a body comprising introducing a solution with an injection system to a fixed position in a body, with the first solution comprising at least one crosslinkable macromer that spontaneously crosslinks in situ to form the crosslinked material, wherein the macromer, within about 1 second of placement at the position, forms the material with sufficient mechanical integrity to remain at the position during the crosslinking process so as to prevent migration of the macromer away from the position.
  • U.S. Patent Application Publication No. 2013/0325059 titled “Non-Clogging Airless Spray for High Viscosity, High Surface Tension Fluids” discloses a medical device for spraying two liquids comprised of a first and second syringe each syringe having an outlet for a first and second liquid; a connecting piece having first and second channels in communication with said syringe outlets terminating in distal component comprised of a spray cap which contain independent fluid passages for said first and second liquids and a first and second exit surface; wherein first and second exit surfaces of said spray cap contain a plurality of small exit apertures and said first and second exit apertures create a spray pattern which combines and mixes said first and second liquids away from the device.
  • Patent Publication No. WO2014/006738A1 titled “TREATMENT DEVICE FOR TREATING INSIDE OF ORGANISM LUMEN” discloses a treatment device for treating the inside of an organism lumen is provided with: a long shaft inserted into a blood vessel; a support section having a proximal end side which is supported by the shaft and also having a distal end side which is capable of expanding and contracting in the direction perpendicular to the axial direction of the shaft; and a deformable application section provided on the distal end side of the support section .
  • the deformable application section is brought into contact with the wall of the blood vessel by the expansion of the distal end side of the support section and has a discharge opening which, when the deformable application section is in contact with the wall of the blood vessel, is located near the wall and can discharge a substance to be applied.
  • Japanese Patent Publication No. JP2011/067491A titled "FLUID JET DEVICE” discloses as an unmet need to effectively penetrate a blood clot and the like with a pulsation flow while removing the whole of blood clot and the like by emitting a jet of a fluid widely, and discloses a solution as being an auxiliary jet orifice that is opened to a direction different from a direction of a jet orifice emitting a pulsation flow, and it is connected to an auxiliary fluid path which is different from a connection fluid path connected to the jet orifice. The fluid is continuously emitted from the auxiliary jet orifice by continuously sending the fluid to the auxiliary fluid path.
  • the pressure of pulsation flow does not decrease because of the auxiliary jet orifice, and the cutting performance of the pulsation flow is kept while the fluid can be emitted from the auxiliary jet orifice within the area where the pulsation flow cannot be emitted.
  • the auxiliary jet orifice can keep the cutting performance by continuously emitting the jet of the fluid even when the pressure of the fluid disperses and decreases by emitting the jet of the fluid widely.
  • the blood clot and the like can be penetrated effectively by the pulsation flow while the whole of blood clot and the like can be removed by emitting the jet of the fluid widely.
  • the present invention is disclosed in the appended set of claims. Briefly, the present inventions are directed to spray tips for multidirectional or three-dimensional spraying of an unmixed two-part sealant and/or hemostat comprising a first biocompatible component and a biocompatible second component onto a tissue or wound comprising: a hollow body having inside a first component distribution compartment and a second component distribution compartment, said compartments not in fluid communication with each other; conduits to supply the first component into the first component distribution compartment and the second component into the second component distribution compartment; and a plurality of first exit orifices on spray tip in fluid communication with the first component distribution compartment and a plurality of second exit orifices on spray tip in fluid communication with the second component distribution compartment.
  • the first exit orifices are positioned alternatingly with said second exit orifices around the spray tip and point towards outside of the spray tip in multiple directions.
  • the spray tip can be further attached through a cannula to component expression pumps containing the first component and second component.
  • the component expression pumps comprise syringes that are conventionally associated with dual syringe devices.
  • the spray tip can further contain a plurality of channels in fluid communication with the component distribution compartments and the exit orifices, and wherein said channels are positioned between said component distribution compartments and the exit orifices.
  • the first component can contain one or more biologic components, preferably fibrinogen and the second component can contain one or more biologic component different from the first biologic component, preferably thrombin and/or thrombin precursors.
  • the exit orifices can be directed towards an area encompassing a solid angle ⁇ between 2 ⁇ and 4 ⁇ steradian.
  • the exit orifices can be directed towards an area encompassing approximately a sphere or approximately a hemisphere, still further an area encompassing a solid angle ⁇ equal to about 2 ⁇ steradian or an area encompassing approximately a cylinder formed circumferentially around the spray tip.
  • the present inventions are also directed to methods of spraying the unmixed two-part sealant or hemostat using the spray tip and associated components described above by simultaneously expressing the first component and the second component from the syringes into the cannula; allowing the first component to enter the first component distribution compartment and the second component to enter the second component distribution compartment inside the spray tip without mixing; and simultaneously spraying the first component through the first exit orifices and the second component through the second exit orifices in multiple directions around the spray tip.
  • the spray can be performed over a solid angle ⁇ between 2 ⁇ and 4 ⁇ steradian.
  • the methods can further comprise the steps of inserting the spray tip into a body cavity or a wound cavity prior to expressing the components; and allowing the first component and the second component intermix in the body cavity or the wound cavity.
  • the present invention relates to a spray tip (spray head) for multidirectional, preferably at least three-dimensional spraying of a two-part adhesive, sealant and/or hemostat (such as fibrin glue comprising fibrinogen and thrombin) onto a tissue or wound without prior mixing of the two-part composition within the spray tip, comprising: a hollow body having inside a first component distribution compartment and a second component distribution compartment, said compartments not in fluid communication with each other; at least two conduits to supply the first component into the first component distribution compartment and the second component into the second component distribution compartment; a plurality of exit orifices directing flow of each part of the two-part sealant towards outside of the spray tip in more than one direction, without mixing.
  • a spray tip spray head
  • a spray tip for multidirectional, preferably at least three-dimensional spraying of a two-part adhesive, sealant and/or hemostat (such as fibrin glue comprising fibrinogen and thrombin) onto a tissue or wound without prior mixing of the two-part composition
  • the first exit orifices are positioned alternatingly with second exit orifices around the spray tip and point towards the outside of the spray tip in multiple directions.
  • there is no mixing of the two-part composition within the spray tip as the mixing can occur on the surfaces onto which the two part composition is sprayed.
  • some mixing can occur in flight between the spray tip exits and surface of the tissue.
  • the spray is performed multi-directionally at the same time, such as circumferentially around the spray tip, such as in 360 degrees around the spray tip.
  • the spray is performed multi-directionally at the same time, with the spray direction schematically indicated by arrows 1 targeting or encompassing substantially a surface of a whole imaginary sphere 5 surrounding the spray tip 10.
  • spray tip 10 has a plurality of exit nozzles or exit orifices 20, 30 through which components A and B of the two-part composition are expelled without mixing. Components A and B are supplied via cannula 50 through individual conduits.
  • spray is performed over a solid angle ⁇ substantially equal or close to 4 ⁇ steradian, such as ⁇ equal from about 3.8 to 4 ⁇ steradian.
  • spray is performed towards a surface of a partial imaginary sphere 5a surrounding the spray tip 10, with no spray in the area of cone 3 which surrounds cannula 50 and expands from spray tip 20 towards imaginary sphere 5a.
  • spray is performed over a solid angle ⁇ corresponding to a partial sphere but larger than a half sphere, i.e. 2 ⁇ 4 ⁇ , such as with solid angle ⁇ equal to 2.5 ⁇ , 3 ⁇ , 3.5 ⁇ , 3.75 ⁇ steradian.
  • spray is performed towards a surface of a partial imaginary half-sphere 5b surrounding the spray tip 10 and opposite cannula 50, with no spray in the area of half-sphere (not shown) which surrounds cannula 50.
  • spray is performed over a solid angle ⁇ corresponding to about half sphere such as with solid angle ⁇ equal to 2 ⁇ steradian.
  • FIG. 4a a schematic representation of an aspect of the present invention is shown, with spray tip 10 attached to cannula 50 containing two conduits 25 and 35 for conducting components A and B, respectively.
  • Opposite spray tip 10 component expression pumps such as syringes 22 and 32 contain components A and B, respectively.
  • Syringes 22 and 32 are connected directly to conduits 25, 35 for conducting components A and B, respectively to spray nozzle 10 without mixing.
  • Spray tip 10 and part of cannula 50 are shown inside body 9 cavity 8.
  • components A and B Upon expressing components A and B from syringes 22 and 32, components A and B travel through conduits 25, 35 into spray tip 10 and are sprayed, separately, from a plurality of orifices 20, 30 forming spray streams 21, 31 of components A and B, respectively. Components A and B are then deposited towards the sides of the spray tip 10 and towards the direction opposite cannula 50 connection to the spray tip 10 onto a surface defined by approximately hemispherical solid angle and shown schematically as dashed line 6. Components A and B, as they are deposited onto tissue surface in the area 6, intermingle and react, resulting in forming of a tissue sealant or hemostat or both.
  • Orifices 20, 30 are positioned on spray tip 10 so as to facilitate uniform distribution of components A and B, in alternating design, for instance in an interdigitated format, checkers format, or similar intermixed format.
  • one orifice 20 is proximate to next orifice 30, which in turn is proximate to next orifice 20 and so on.
  • each orifice 20 is at least partially surrounded by several orifices 30, while each orifice 30 is at least partially surrounded by several orifices 20.
  • a cluster of orifices 20 is next to a cluster of orifices 30 which is in turn proximate to next cluster of orifices 20 and so on.
  • Fig. 4b a schematic representation of an embodiment of the present invention similar to the embodiment of Fig. 4a is shown.
  • components A and B are deposited towards the sides of the spray tip 10 and circumferentially around spray tip 10, but not towards the direction opposite cannula 50 connection to the spray tip 10, with resulting spray onto a surface defined by approximately cylindrical shape and shown schematically as dashed line 7.
  • Spray tip 10 comprises a hollow body with two separate compartments inside, component A distribution compartment 23 and component B distribution compartment 33.
  • Component A distribution compartment 23 is in fluid communication with conduit 25 and with all orifices 20.
  • Component B distribution compartment 33 is in fluid communication with conduit 35 and with all orifices 30.
  • components A and B travel through conduits 25, 35 into spray tip 10 and enter respectively component A distribution compartment 23 and component B distribution compartment 33, after which components A and B are sprayed, separately, from respectively plurality of orifices 20, 30 forming spray streams 21, 31 of components A and B respectively.
  • sprays streams 21, 31 are schematically shown by respectively light and dark arrows in Fig. 5 , but it is understood that every exit orifice 20, 30 will generate spray streams 21, 31.
  • the spray is performed in all directions encompassing a sphere, i.e. over a solid angle 4 ⁇ .
  • orifices 20, 30 are positioned on spray tip 10 in alternating design or intermingled, with one type following another so as to facilitate uniform distribution of components A and B.
  • Such alternating, interlaced, or interspersed positioning of both types of orifices 20, 30 facilitates a good mixing of components A and B when they are deposited on to tissue or wound surface.
  • spraying is performed only over about a half-sphere opposite cannula 50, with no spray performed in the direction of cannula 50.
  • spray tip 10 has substantially a spherical shape, with arrays of exit orifices 20, 30 arranged in alternating longitudinal zones.
  • spray tip 10 having a generally hollow cylindrical shape attached to cannula 50 via adapter 12.
  • spray tip 10 comprises a hollow body with two separate compartments inside, component A distribution compartment 23 and component B distribution compartment 33 separated by separator 13.
  • Spray tip 10 is capped at the end opposite adapter 12 by endcap 11.
  • Component A distribution compartment 23 is in fluid communication with conduit 25 and with all orifices 20.
  • Component B distribution compartment 33 is in fluid communication with conduit 35 and with all orifices 30.
  • components A and B travel through conduits 25, 35 into spray tip 10 and enter respectively component A distribution compartment 23 and component B distribution compartment 33, after which components A and B are sprayed, separately, from respectively plurality of orifices 20, 30.
  • all component A spraying orifices 20 are located around component A distribution compartment 23 in the portion of the spray tip 10 proximal to adapter 12, while all component B spraying orifices 30 are located around component B distribution compartment 33 in the portion of the spray tip 10 proximal to endcap 11. No mixing of components A and B is performed inside spray tip 10.
  • spray tip 10 having a generally hollow cylindrical shape attached to cannula 50 via adapter 12.
  • spray tip 10 comprises a hollow body with two separate compartments inside, component A distribution compartment 23 and component B distribution compartment 33 separated by separator 13.
  • Spray tip 10 is capped at the end opposite adapter 12 by endcap 11.
  • Component A distribution compartment 23 is in fluid communication with conduit 25 and component B distribution compartment 33 is in fluid communication with conduit 35.
  • a plurality of axial channels 16 and 17 run axially along the spray tip 10 cylindrical body, and are positioned one after another around the circumference of the spray tip 10.
  • Axial channels 16 are in fluid communication with component A distribution compartment 23 through vias or openings 18, and are also in fluid communication with all orifices 20.
  • Axial channels 17 are in fluid communication with component B distribution compartment 33 through vias 19, and are also in fluid communication with all orifices 30.
  • Components A and B travel through conduits 25, 35 (not shown in Figs 10-13 ) into spray tip 10 and enter respectively component A distribution compartment 23 and component B distribution compartment 33, after which components A and B are passing through correspondingly vias 18 and 19 into axial channels 16 and 17 and are sprayed, separately, from respectively plurality of orifices 20, 30.
  • all component A spraying orifices 20 are in several axial arrays arranged along the whole or most of the length of spray tip 10.
  • all component B spraying orifices 30 are in several axial arrays arranged along the whole or most of the length of spray tip 10.
  • Arrays of orifices 20 are interlaced (or arranged one after another in alternating design) with arrays of orifices 30 so that around the circumference of the cylindrical spray tip 10 array of orifices 20 is followed by array of orifices 30, followed again by array of orifices 20. No mixing of components A and B is performed inside spray tip 10.
  • FIG. 14 an alternative aspect of the present invention is schematically shown, with spray tip 10 having two internal generally helical channels 27 and 37 which are fed components A and B from conduits 25 and 35 respectively, resulting in exit orifices 20 and 30 positioned around the spray tip 10 and enabling spraying in directions orthogonal to the spray tip 10 cylindrical surface.
  • Channels 27 and 37 correspond to component A distribution compartment 23 and component B distribution compartment 33 respectively.
  • Optional additional exit orifices 28 and 38 are located on the base of cylindrical tip 10 for spraying also in the axial direction, thus providing a semispherical spray pattern. No mixing of components A and B is performed inside spray tip 10.
  • Figs. 15 and 16 an alternative aspect of the present invention is shown, with spray tip 10 formed by two tubes 29 and 39 positioned in parallel and side by side between adapter 12 and endcap 11, with a gap between tubes 29 and 39 ranging from about 1 mm to about 15 mm, such as 3, 5, 7, 10 mm.
  • Adapter 12 connects tip 10 to cannula 50.
  • Exit orifices 20 are openings or apertures formed in tube 29 along its length and around its circumference.
  • Exit orifices 30 are openings or apertures formed in tube 39 along its length and around its circumference.
  • components A and B travel from cannula 50 into closed-end tubes 29 and 39.
  • Components A and B are sprayed, separately, from respectively plurality of orifices 20, 30.
  • Tubes 29 and 39 correspond to component A distribution compartment 23 and component B distribution compartment 33 respectively.
  • No exit orifices 20, 30 are formed in tubes 29, 39 facing the opposite tube to prevent spraying component A onto component B exit orifices and vice versa.
  • tubes 29 and 39 are not closed-end tubes. No mixing of components A and B is performed inside spray tip 10.
  • a multi-directional or multidimensional or three dimensional spray tip or spray head for delivery of a liquid sealant, including single part sealant, more preferably multi-part sealant, such as a two-part sealant or hemostat or both, such as liquid fibrin sealant comprising solutions of fibrinogen and thrombin, capable of dispensing a fine spray or mist onto the lung, pleura and chest wall simultaneously in several directions.
  • a liquid sealant including single part sealant, more preferably multi-part sealant, such as a two-part sealant or hemostat or both, such as liquid fibrin sealant comprising solutions of fibrinogen and thrombin, capable of dispensing a fine spray or mist onto the lung, pleura and chest wall simultaneously in several directions.
  • the thin layer of sealant coated on the surface of the lung would contact the sealant coated on the chest wall to adhere the surfaces while minimizing the sealant needed to achieve such adherence and to seal air leaks.
  • this concept of three dimensional spraying or misting would also be applicable to other
  • Simultaneous multidirectional spraying allows coating of tissue surfaces on a single pass delivery of sealant.
  • unidirectional forward spraying both pleura surfaces can't be coated simultaneously, and requires additional time and multiple passes to coat all surfaces uniformly.
  • No pressurized gas e.g. air, CO2, etc.
  • the delivery can be achieved by manual delivery and application of the liquid components using a double barrel syringe system, or modification thereof.
  • the use of an air-less or gas-less spray delivery system of the biologics improves the safety and ease of use of the system.
  • the present invention is not associated with clogging of the spray tip since the components are always kept separated within the device and spray tip/spray head. No changing of clogged tips will be required. Clogging can occur with some fibrin sealant delivery devices since mixing occurs within the tip. Changing of tips extends the procedural time and interrupts the surgeon's rhythm.
  • the two liquid components of the present invention react on the tissue surface upon contact. Adhesion between the lung and chest wall is created when the two liquid components react on the tissue surface. This reaction reduces/eliminates the criticality of the timing between application of the sealant and expansion of the lung.
  • the spraying and misting action can deliver the sealant in all directions from the spray tip, nearly 360° rather than the traditional cone-shaped pattern of most spray tips.
  • the sealant could be delivered as a burst which could simultaneously coat the surfaces within the thoracic cavity to a deflated or partially deflated lung.
  • the spray head could be used in open procedures or during endoscopic/VATS (video-assisted thoracoscopic surgery) procedures.
  • the spray tip is designed to maintain isolation of the components A and B until after they leave the device and prevents clogging of the device during interrupted application.
  • the resulting spray pattern from the device is a circular array of streams projecting radially from the spray head.
  • the streams are comprised of alternating biologics. When the streams hit the walls of the body cavity of the patient, they disperse and comingle, allowing them to polymerize into the desired sealing structure.
  • the internal diameter of conduits 25, 35 is from about 0.5 mm to about 5 mm, more preferably 1 to 3 mm, such as 1, 1.5, 2, 3 mm.
  • the diameter of exit orifices 20, 30 is from about 0.1 mm to about 2 mm, more preferably 0.2 mm to 1 mm, such as 0.25, 0.5 0.75 mm.
  • exit orifices 20, 30 are drilled perpendicular to the surface if the spay head 10, resulting in spray is perpendicular to the spray head 10 surface.
  • at least some exit orifices 20, 30 are drilled under angle and not perpendicular to the surface if the spay head 10, resulting in some spray directions is not perpendicular to the spray head 10 surface.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mechanical Engineering (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Surgical Instruments (AREA)

Claims (8)

  1. Embout (10) de pulvérisation destiné à la pulvérisation multidirectionnelle ou tridimensionnelle d'un agent d'étanchéité et/ou hémostatique à deux constituants non mélangés comportant un premier composant biocompatible (A) et un second composant biocompatible (B) sur un tissu ou une plaie, comportant :
    un corps creux à l'intérieur duquel se trouvent un compartiment (23) de distribution de premier composant et un compartiment (33) de distribution de second composant, lesdits compartiments n'étant pas en communication fluidique entre eux ;
    des conduits (25, 35) servant à amener le premier composant jusque dans le compartiment de distribution de premier composant et le second composant jusque dans le compartiment de distribution de second composant ;
    une pluralité de premiers orifices (20) de sortie sur ledit embout de pulvérisation en communication fluidique avec le compartiment de distribution de premier composant et une pluralité de seconds orifices (30) de sortie sur ledit embout de pulvérisation en communication fluidique avec le compartiment de distribution de second composant ;
    lesdits premiers orifices de sortie étant positionnés en alternance avec lesdits seconds orifices de sortie autour de l'embout de pulvérisation ;
    lesdits orifices de sortie étant orientés vers l'extérieur de l'embout de pulvérisation dans des directions multiples ; et
    caractérisé en ce qu'un diagramme de pulvérisation résultant issu de l'embout de pulvérisation comporte un agencement circulaire de flux faisant saillie radialement à partir de l'embout de pulvérisation, lesdits orifices de sortie étant dirigés vers une zone couvrant approximativement une sphère.
  2. Embout de pulvérisation selon la revendication 1, ledit embout (10) de pulvérisation étant en outre relié par l'intermédiaire d'une canule (50) à des pompes (22, 32) d'expression de composants contenant le premier composant et le second composant.
  3. Embout de pulvérisation selon la revendication 2, lesdites pompes (22, 32) d'expression de composants comportant des seringues.
  4. Embout de pulvérisation selon la revendication 1, ledit embout (10) de pulvérisation contenant en outre une pluralité de canaux (16, 17) en communication fluidique avec les compartiments (23, 33) de distribution de composants et les orifices (20, 30) de sortie, et lesdits canaux étant positionnés entre lesdits compartiments de distribution de composants et les orifices de sortie.
  5. Embout de pulvérisation selon la revendication 1, le premier composant (A) comportant du fibrinogène et le second composant (B) comportant de la thrombine.
  6. Embout de pulvérisation selon l'une quelconque des revendications précédentes, l'embout de pulvérisation présentant une forme sensiblement sphérique, des agencements desdits orifices de sortie étant disposés dans des zones longitudinales alternées.
  7. Procédé de pulvérisation de l'agent d'étanchéité ou hémostatique à deux constituants non mélangés à l'aide de l'embout (10) de pulvérisation selon la revendication 3, comportant les étapes consistant à :
    a) exprimer simultanément le premier composant et le second composant à partir des seringues (22, 32) jusque dans la canule (50) ;
    b) permettre au premier composant d'entrer dans le compartiment (23) de distribution de premier composant et au second composant d'entrer dans le compartiment (33) de distribution de second composant à l'intérieur de l'embout de pulvérisation sans se mélanger ;
    c) pulvériser simultanément le premier composant à travers les premiers orifices (20) de sortie et le second composant à travers les seconds orifices (30) de sortie dans des directions multiples autour de l'embout de pulvérisation ; et
    caractérisé en ce qu'un diagramme de pulvérisation résultant issu de l'embout de pulvérisation est un agencement circulaire de flux faisant saillie radialement à partir de l'embout de pulvérisation, lesdits orifices de sortie étant dirigés vers une zone couvrant approximativement une sphère.
  8. Procédé selon la revendication 7, ladite étape c) étant réalisée sans mélanger le premier composant et le second composant dans ledit embout de pulvérisation.
EP17772786.4A 2016-08-16 2017-08-10 Pointes de pulvérisation pour distribution simultanée multidirectionnelle de fluides dissemblables Active EP3500182B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP20197424.3A EP3788964A1 (fr) 2016-08-16 2017-08-10 Pointes de pulvérisation pour distribution simultanée multidirectionnelle de fluides dissemblables

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/238,105 US10625032B2 (en) 2016-08-16 2016-08-16 Spray tips for simultaneous multi-directional delivery of dissimilar fluids
PCT/US2017/046210 WO2018034922A1 (fr) 2016-08-16 2017-08-10 Pointes de pulvérisation pour distribution simultanée multidirectionnelle de fluides dissemblables

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP20197424.3A Division-Into EP3788964A1 (fr) 2016-08-16 2017-08-10 Pointes de pulvérisation pour distribution simultanée multidirectionnelle de fluides dissemblables
EP20197424.3A Division EP3788964A1 (fr) 2016-08-16 2017-08-10 Pointes de pulvérisation pour distribution simultanée multidirectionnelle de fluides dissemblables

Publications (2)

Publication Number Publication Date
EP3500182A1 EP3500182A1 (fr) 2019-06-26
EP3500182B1 true EP3500182B1 (fr) 2020-12-16

Family

ID=59969214

Family Applications (2)

Application Number Title Priority Date Filing Date
EP20197424.3A Withdrawn EP3788964A1 (fr) 2016-08-16 2017-08-10 Pointes de pulvérisation pour distribution simultanée multidirectionnelle de fluides dissemblables
EP17772786.4A Active EP3500182B1 (fr) 2016-08-16 2017-08-10 Pointes de pulvérisation pour distribution simultanée multidirectionnelle de fluides dissemblables

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP20197424.3A Withdrawn EP3788964A1 (fr) 2016-08-16 2017-08-10 Pointes de pulvérisation pour distribution simultanée multidirectionnelle de fluides dissemblables

Country Status (4)

Country Link
US (1) US10625032B2 (fr)
EP (2) EP3788964A1 (fr)
CN (1) CN109640834B (fr)
WO (1) WO2018034922A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10981187B2 (en) 2018-06-21 2021-04-20 Melissa McGarry Devices and methods for multi-directional fluid pumping
US11766383B2 (en) 2018-06-25 2023-09-26 Gary J. Pontecorvo Disposable nasal and eye wash dispenser
US11358165B2 (en) * 2019-10-04 2022-06-14 Ethicon, Inc. Spray devices having side-by-side spray tips for dispensing two fluids that chemically react together
IT202000019642A1 (it) * 2020-08-07 2022-02-07 Gaetano Mauro Erogatore di polvere emostatica ad aria compressa, dotato di cannula biocompatibile, da usare nel primo trattamento di ferite da arma da fuoco o da taglio
US20220054771A1 (en) * 2020-08-19 2022-02-24 Boston Scientific Scimed, Inc. Delivery device and methods of use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116315A (en) 1989-10-03 1992-05-26 Hemaedics, Inc. Biological syringe system
PT689874E (pt) 1994-06-28 2002-03-28 Aventis Behring Gmbh Dispositivo para a pulverizacao de uma mistura de dois componentes
US5605541A (en) 1994-12-07 1997-02-25 E. R. Squibb And Sons, Inc. Fibrin sealant applicatoor
US5814022A (en) 1996-02-06 1998-09-29 Plasmaseal Llc Method and apparatus for applying tissue sealant
US5759169A (en) 1996-03-13 1998-06-02 New York Blood Center Inc. Fibrin sealant glue-gun
WO1998002098A1 (fr) 1996-07-12 1998-01-22 Baxter International Inc. Dispositif distributeur de fibrine et procede de formation de fibrine sur une surface
US20030191496A1 (en) 1997-03-12 2003-10-09 Neomend, Inc. Vascular sealing device with microwave antenna
US6063055A (en) 1997-04-14 2000-05-16 Biosurgical Corporation Turbulence mixing head for a tissue sealant applicator and spray head for same
JP2001520086A (ja) * 1997-10-22 2001-10-30 ミネソタ マイニング アンド マニュファクチャリング カンパニー 粘着性組織密封材用ディスペンサ
US6152943A (en) 1998-08-14 2000-11-28 Incept Llc Methods and apparatus for intraluminal deposition of hydrogels
US6168335B1 (en) 1998-08-18 2001-01-02 Arich, Inc. Applicator and dispensing device using same
SE0100091D0 (sv) 2001-01-12 2001-01-12 Pharmacia Ab A device and a method for dispensing at least two mutually reactive components
US6863660B2 (en) 2002-03-27 2005-03-08 Hapio Biotech, Inc. Fibrin applicator pistol
AU2005295477B2 (en) 2004-10-18 2011-11-24 Covidien Lp Structure for applying sprayable wound treatment material
US7717313B2 (en) 2004-10-18 2010-05-18 Tyco Healthcare Group Lp Surgical apparatus and structure for applying sprayable wound treatment material
AU2006205001B2 (en) * 2005-01-12 2011-05-26 Baxter Healthcare S.A. Hand triggered tissue sealant spray apparatus and system
US7611494B2 (en) 2005-02-08 2009-11-03 Confluent Surgical, Inc. Spray for fluent materials
WO2006102472A1 (fr) 2005-03-24 2006-09-28 Diageo Great Britain Limited Dispositif de distribution de liquide a compartiments multiples et procedes d'utilisation
DE202005006547U1 (de) 2005-04-22 2006-06-08 Brugger, Gerhard Applikator für zwei oder mehr Komponenten
JP5007056B2 (ja) * 2006-03-13 2012-08-22 テルモ株式会社 塗布具
US7861893B2 (en) 2006-11-10 2011-01-04 Ethicon Endo-Surgery, Inc. Adhesive dispenser for surgery
US8333787B2 (en) 2007-12-31 2012-12-18 St. Jude Medical Puerto Rico Llc Vascular closure device having a flowable sealing material
US8408480B2 (en) 2008-04-25 2013-04-02 Confluent Surgical, Inc. Self-cleaning spray tip
DE102009055227B3 (de) * 2009-12-23 2011-06-22 Human Med AG, 19061 Verfahren zur Förderung eines Fluids sowie Vorrichtung zur Erzeugung eines Volumenstromes
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
WO2010055447A1 (fr) 2008-11-11 2010-05-20 Mauro Bonino Dispositif d'application de colle sur des tissus à relier
US8377507B2 (en) * 2009-05-06 2013-02-19 Synthes Usa, Llc Method and apparatus for applying a sealant
JP2011067491A (ja) 2009-09-28 2011-04-07 Seiko Epson Corp 流体噴射装置
WO2013137062A1 (fr) 2012-03-15 2013-09-19 テルモ株式会社 Applicateur
US20130325059A1 (en) 2012-06-01 2013-12-05 Devicegenerics, Inc. Non-Clogging Airless Spray for High Viscosity, High Surface Tension Fluids
WO2014006738A1 (fr) 2012-07-06 2014-01-09 テルモ株式会社 Dispositif de traitement pour traiter l'intérieur d'une lumière d'organisme
US9119606B2 (en) * 2013-01-21 2015-09-01 Ethicon, Inc. Sealant delivery device for anastomotic stapler
CN105342687B (zh) * 2015-09-26 2023-08-29 赵全明 用于微创外科手术的骨水泥推注器

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
US20180050163A1 (en) 2018-02-22
CN109640834B (zh) 2021-10-08
CN109640834A (zh) 2019-04-16
WO2018034922A1 (fr) 2018-02-22
EP3500182A1 (fr) 2019-06-26
EP3788964A1 (fr) 2021-03-10
US10625032B2 (en) 2020-04-21

Similar Documents

Publication Publication Date Title
EP3500182B1 (fr) Pointes de pulvérisation pour distribution simultanée multidirectionnelle de fluides dissemblables
JP6636507B2 (ja) 液体並びに粉末止血剤及びシーラントを共送達するための方法及び装置
AU721371B2 (en) Devices and methods for applying a mixture of two or more liquid components to form a biomaterial
US8684282B2 (en) Adjustable spray pattern atomizer
US20020198564A1 (en) Self-cleaning fluid delivery device for medical applications
EP2895259B1 (fr) Ensemble embout sans air et anti-obstruction et dispositif associé
US8523806B2 (en) Sprayer
US20130325059A1 (en) Non-Clogging Airless Spray for High Viscosity, High Surface Tension Fluids
US20020165483A1 (en) Gas assisted spray applicator
US20030209612A1 (en) Spray head for applying a multi-component mixture
CN110753518B (zh) 具有漏斗进料套件的双注射器
KR20220073793A (ko) 함께 화학 반응하는 두 가지 유체를 분배하기 위한 나란한 분무 팁을 갖는 분무 장치
CN107106152B (zh) 至医疗施用装置的添加件
EP2695626B1 (fr) Dispositif de déchargement d'un liquide réactif
JP2001057979A (ja) 生体組織接着剤塗布用具
EP3352679B1 (fr) Pointes de pulvérisation ou de goutte-à-goutte dotées de multiples canaux de sortie
JP2000354797A (ja) 生体組織接着剤塗布用具
US20230309978A1 (en) Sealant applicators having mixing and spraying assemblies with malleable sections and spray tips having reduced dimensions
WO2022131249A1 (fr) Dispositif d'injection de liquide médicamenteux pour corps vivant
JP3483250B2 (ja) 生体接着剤噴霧ノズル
JP4141944B2 (ja) 生体組織用薬剤の供給器具
JP2003235977A (ja) 生体組織接着剤塗布用具

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20190315

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200217

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTG Intention to grant announced

Effective date: 20200525

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20200626

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017029694

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1344840

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210317

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210316

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1344840

Country of ref document: AT

Kind code of ref document: T

Effective date: 20201216

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20201216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210316

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210416

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MD

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017029694

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210416

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

26N No opposition filed

Effective date: 20210917

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20210831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20210416

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210810

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210831

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20220630

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20220712

Year of fee payment: 6

Ref country code: DE

Payment date: 20220608

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20220709

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20170810

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602017029694

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20230810

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216

VS25 Lapsed in a validation state [announced via postgrant information from nat. office to epo]

Ref country code: MA

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20201216